Boosting immune response against cervical cancer: A combined approach using oncolytic virus and targeted therapies

Our findings highlight the potential to improve outcomes in cervical cancer associated with HPV through a multi-faceted approach incorporating NDV, Everolimus, and Beclin-1. This therapeutic strategy not only hinders tumor growth but also strengthens the immune system's ability to fight against cancer. These results prompt further exploration of this combination in clinical trials, with the goal of offering new treatment avenues for patients who have limited choices.